SG149814A1 - Compositions and methods for treating diabetes - Google Patents

Compositions and methods for treating diabetes

Info

Publication number
SG149814A1
SG149814A1 SG200809465-8A SG2008094658A SG149814A1 SG 149814 A1 SG149814 A1 SG 149814A1 SG 2008094658 A SG2008094658 A SG 2008094658A SG 149814 A1 SG149814 A1 SG 149814A1
Authority
SG
Singapore
Prior art keywords
diabetes
methods
treating diabetes
compositions
prevent
Prior art date
Application number
SG200809465-8A
Other languages
English (en)
Inventor
Bill Piu Chan
Gary Kwan Po Wong
Jinxian Xu
Francis Chi
Original Assignee
Omega Bio Pharma Ip3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omega Bio Pharma Ip3 Ltd filed Critical Omega Bio Pharma Ip3 Ltd
Publication of SG149814A1 publication Critical patent/SG149814A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
SG200809465-8A 2003-12-19 2004-12-20 Compositions and methods for treating diabetes SG149814A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53111903P 2003-12-19 2003-12-19
US59170904P 2004-07-27 2004-07-27

Publications (1)

Publication Number Publication Date
SG149814A1 true SG149814A1 (en) 2009-02-27

Family

ID=34742984

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200809465-8A SG149814A1 (en) 2003-12-19 2004-12-20 Compositions and methods for treating diabetes

Country Status (18)

Country Link
US (2) US7442720B2 (ja)
EP (1) EP1696897B1 (ja)
JP (1) JP4845740B2 (ja)
KR (1) KR101329369B1 (ja)
CN (1) CN101897970A (ja)
AR (1) AR047779A1 (ja)
AT (1) ATE515261T1 (ja)
AU (1) AU2004308934B2 (ja)
BR (1) BRPI0417829A (ja)
CA (1) CA2549717C (ja)
HK (1) HK1099507A1 (ja)
IL (1) IL176259A (ja)
MX (1) MXPA06007100A (ja)
MY (1) MY143799A (ja)
RU (1) RU2367423C2 (ja)
SG (1) SG149814A1 (ja)
TW (1) TWI350751B (ja)
WO (1) WO2005063226A1 (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4966665B2 (ja) 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
CN101897970A (zh) * 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
WO2005060342A2 (en) * 2003-12-19 2005-07-07 Omega Bio-Pharma International Ltd. Cysteamine compounds for treating allergy
EP1706104A2 (en) * 2004-01-13 2006-10-04 Omega Bio-Pharma (I.P.2) Limited Methods for treating stress and affecting biological immune systems using a cysteamine compound
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete
WO2006002868A1 (en) * 2004-06-30 2006-01-12 Omega Bio-Pharma (I.P.1) Limited Materials and methods for improving shellfish health, immunity and growth
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
AU2013267044B2 (en) * 2006-01-27 2016-07-07 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
HUE049307T2 (hu) * 2006-01-27 2020-09-28 Univ California Bélben oldódó bevonattal ellátott ciszteamin-bitartrát és cisztamin
US8138227B2 (en) * 2006-07-06 2012-03-20 Trustees Of Dartmouth College Method for inhibiting or reversing non-enzymatic glycation
US7993687B2 (en) 2006-07-12 2011-08-09 Julianne Marie Kawa Compositions and methods for management of diabetes
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
ES2417179T3 (es) 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina
US10175251B2 (en) * 2010-04-13 2019-01-08 M-Lab Gmbh Diagnostic methods for glaucoma
US8815562B2 (en) 2010-04-15 2014-08-26 The Regenys of the University of Michigan Biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9480663B2 (en) * 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
BR112013017411B1 (pt) 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Uso de uma composição compreendendo metformina ou um sal da mesma
CA2825162A1 (en) * 2011-02-02 2012-08-09 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20140322315A1 (en) * 2011-11-22 2014-10-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
EA033067B1 (ru) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015015403A2 (en) * 2013-08-01 2015-02-05 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
CA2959965A1 (en) * 2014-09-02 2016-03-10 Bhupinder Singh Pharmaceutical formulations comprising tetrahydrocurcumin and lipids
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
EP3316877B1 (en) 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
US20180353523A1 (en) * 2015-09-22 2018-12-13 Viking Therapeutics Conjoint therapies with inhibitors of glucose production
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CN106620715B (zh) * 2015-11-04 2021-04-06 江苏恒瑞医药股份有限公司 一种治疗糖尿病的药物组合物及其制备方法
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US10155948B2 (en) 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
KR101881662B1 (ko) * 2016-05-12 2018-07-26 강원대학교산학협력단 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법
EP3573994A4 (en) * 2017-01-25 2020-11-11 Adare Pharmaceuticals, Inc. MEDICINES OF CYSTEAMINE
CN109439553B (zh) * 2018-12-26 2020-08-21 华熙生物科技股份有限公司 产麦角硫因的菌株及其筛选方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
DE3343141A1 (de) 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
DE3883712T2 (de) * 1987-06-04 1993-12-16 Massachusetts Inst Technology Chemisches verhindern oder rückgängigmachen von star-erkrankungen durch phasentrennungsinhibitoren.
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
RU2135176C1 (ru) 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
FR2716625B1 (fr) 1994-02-25 1996-04-26 Gouchet Franck Arno Préparation et utilisation de formes pharmaceutiques et cosmétiques contenant des composés d'inclusion avec les cyclodextrines de cystéamine, sels de cystéamine, ou dérivés de la cystéamine, sous forme de sel ou non.
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
KR100245077B1 (ko) * 1997-04-25 2000-02-15 김영환 반도체 메모리 소자의 딜레이 루프 럭크 회로
US6100736A (en) * 1997-06-05 2000-08-08 Cirrus Logic, Inc Frequency doubler using digital delay lock loop
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US6621496B1 (en) * 1999-02-26 2003-09-16 Micron Technology, Inc. Dual mode DDR SDRAM/SGRAM
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
SK287810B6 (sk) 1999-11-03 2011-10-04 Bristol-Myers Squibb Company Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu
US6630176B2 (en) 2000-03-07 2003-10-07 Mount Sinai School Of Medicine Of New York University Herbal remedies for treating allergies and asthma
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
AU2001266861A1 (en) 2000-06-12 2001-12-24 Randell L. Mills Photocleavable prodrugs for selective drug delivery
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
JP3715529B2 (ja) 2000-12-19 2005-11-09 雅嗣 田中 アルコール代謝促進剤
US6746578B2 (en) * 2001-05-31 2004-06-08 International Business Machines Corporation Selective shield/material flow mechanism
CN1694695A (zh) * 2002-11-07 2005-11-09 帝斯曼知识产权资产管理有限公司 包含表没食子儿茶素没食子酸酯的新颖的营养药物性组合物
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
JP4966665B2 (ja) 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
CN101897970A (zh) * 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
WO2005060342A2 (en) 2003-12-19 2005-07-07 Omega Bio-Pharma International Ltd. Cysteamine compounds for treating allergy
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete

Also Published As

Publication number Publication date
HK1099507A1 (en) 2007-08-17
EP1696897A1 (en) 2006-09-06
IL176259A (en) 2016-02-29
RU2367423C2 (ru) 2009-09-20
EP1696897A4 (en) 2008-12-10
CA2549717C (en) 2012-11-13
WO2005063226A1 (en) 2005-07-14
TW200524583A (en) 2005-08-01
IL176259A0 (en) 2006-10-05
CA2549717A1 (en) 2005-07-14
AR047779A1 (es) 2006-02-22
MY143799A (en) 2011-07-15
MXPA06007100A (es) 2007-01-19
AU2004308934B2 (en) 2010-04-01
ATE515261T1 (de) 2011-07-15
TWI350751B (en) 2011-10-21
US20050137125A1 (en) 2005-06-23
BRPI0417829A (pt) 2007-04-10
JP2007514771A (ja) 2007-06-07
KR20070004569A (ko) 2007-01-09
CN101897970A (zh) 2010-12-01
RU2006126062A (ru) 2008-01-27
KR101329369B1 (ko) 2013-11-14
US7442720B2 (en) 2008-10-28
AU2004308934A1 (en) 2005-07-14
US8188151B2 (en) 2012-05-29
US20090048154A1 (en) 2009-02-19
EP1696897B1 (en) 2011-07-06
JP4845740B2 (ja) 2011-12-28

Similar Documents

Publication Publication Date Title
SG149814A1 (en) Compositions and methods for treating diabetes
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
TNSN00206A1 (en) Method for treating diabetes
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
IL208184A0 (en) Glp-1, and methods for treating diabetes
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
HUP0300218A2 (hu) Eljárás diabetes kezelésére, metformin és glybarid kombinációját alkalmazva
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2005039554A3 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
EA200801305A1 (ru) Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
IL173822A0 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
BR0111464A (pt) Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
GB9421472D0 (en) Novel methods
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
Jagadeeshwaran et al. Pharmaco-prosthodontics revisited